Kymera KYMR reported a fourth-quarter 2025 loss of 97 cents per share, wider than the Zacks Consensus Estimate of a loss of 77 cents. In the year-ago quarter, Kymera reported a loss of 88 cents per ...
Kymera Therapeutics (NASDAQ:KYMR) presented its fourth quarter and full year 2025 results on February 26, 2026, revealing a stark contrast between clinical pipeline advancement and financial ...
The MarketWatch News Department was not involved in the creation of this content. KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 ...
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...
Abstract: We present LLM-KT, a flexible framework designed to enhance collaborative filtering (CF) models by seamlessly integrating LLM (Large Language Model)-generated features. Unlike existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results